Metformin impairs homing ability and efficacy of mesenchymal stem cells for cardiac repair in streptozotocin-induced diabetic cardiomyopathy in rats
Hania Ibrahim Ammar, Asmaa Mohammed ShamsEldeen, Heba Samy Shoukry, Hend Ashour, Samaa Samir Kamar, Laila Ahmed Rashed, Mostafa Fadel, Abhay Srivastava, Sanjiv Dhingra
Abstract
Metformin treatment reduces the efficacy of mesenchymal stem cell therapy for cardiac repair during diabetic cardiomyopathy. Stem cell therapy in diabetics may be more effective in combination with AMPK inhibitors.
Topics & Concepts
MetforminHoming (biology)StreptozotocinDiabetic cardiomyopathyMesenchymal stem cellMedicineCardiomyopathyDiabetes mellitusInternal medicineCardiologyEndocrinologyHeart failureBiologyPathologyEcologyMetabolism, Diabetes, and CancerPancreatic function and diabetesCardiovascular Function and Risk Factors